These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25772457)

  • 1. The era of immuno-oncology: are we there yet?
    Villasboas JC; Ansell SM
    Oncology (Williston Park); 2015 Mar; 29(3):204-5. PubMed ID: 25772457
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.
    Siddiqi T; Rosen ST
    Oncology (Williston Park); 2015 Mar; 29(3):198-203. PubMed ID: 25772456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation cancer biologics shine in studies.
    Dalzell MD
    Manag Care; 2013 Oct; 22(10):58-9. PubMed ID: 24350384
    [No Abstract]   [Full Text] [Related]  

  • 4. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Bello C; Veliz M; Pinilla-Ibarz J
    Expert Rev Clin Immunol; 2011 May; 7(3):295-300. PubMed ID: 21595596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine (Treanda) for CLL and NHL.
    Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789
    [No Abstract]   [Full Text] [Related]  

  • 6. Protein design labs begins Phase I trial of Remitogen in cancer patients with solid tumors.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):246. PubMed ID: 12113045
    [No Abstract]   [Full Text] [Related]  

  • 7. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
    Takeshita A; Shinjo K; Yamakage N; Ono T; Hirano I; Matsui H; Shigeno K; Nakamura S; Tobita T; Maekawa M; Ohnishi K; Sugimoto Y; Kiyoi H; Naoe T; Ohno R
    Br J Haematol; 2009 Jun; 146(1):34-43. PubMed ID: 19388933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical data expected for nucleotide GS 9219.
    AIDS Patient Care STDS; 2007 Apr; 21(4):289-90. PubMed ID: 17506142
    [No Abstract]   [Full Text] [Related]  

  • 9. Small molecules, big challenges.
    Cheson BD
    Oncology (Williston Park); 2015 Apr; 29(4):308-c3. PubMed ID: 25920930
    [No Abstract]   [Full Text] [Related]  

  • 10. 2019 ASH Annual Meeting.
    Yaqub F
    Lancet Haematol; 2020 Jan; 7(1):e12-e13. PubMed ID: 31859224
    [No Abstract]   [Full Text] [Related]  

  • 11. Meeting highlights from 2nd symposium on controversies and clinical challenges in myeloma, lymphoma and leukemia.
    Reddy GK; D'Orazio A
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):170-4. PubMed ID: 16354320
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibody-drug conjugates in non-Hodgkin lymphoma.
    Lim ST
    Lancet Oncol; 2015 Jun; 16(6):607-8. PubMed ID: 25925618
    [No Abstract]   [Full Text] [Related]  

  • 13. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C; Castillo J
    Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropenia in patients treated with rituximab.
    Voog E; Morschhauser F; Solal-Céligny P
    N Engl J Med; 2003 Jun; 348(26):2691-4; discussion 2691-4. PubMed ID: 12826650
    [No Abstract]   [Full Text] [Related]  

  • 16. 2-Chlorodeoxyadenosine, a "novel" agent in the treatment of both lymphoid and myeloid malignancies.
    Lauria F
    Haematologica; 1992; 77(6):443-5. PubMed ID: 1363233
    [No Abstract]   [Full Text] [Related]  

  • 17. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NCCN: New directions in chronic lymphocytic leukemia.
    O'Brien S
    Cancer Control; 2001; 8(6 Suppl 2):114-7. PubMed ID: 11760553
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibodies in chronic lymphocytic leukemia.
    Ferrajoli A; Faderl S; Keating MJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug essentials. An alkylating agent for CLL and NHL.
    Wilkes GM
    Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):55-6. PubMed ID: 19856600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.